Sedation - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sedation - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Sedation - Pipeline Review, H2 2015', provides an overview of the Sedation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sedation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sedation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sedation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sedation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sedation Overview 7
Therapeutics Development 8
Pipeline Products for Sedation - Overview 8
Pipeline Products for Sedation - Comparative Analysis 9
Sedation - Therapeutics under Development by Companies 10
Sedation - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Sedation - Products under Development by Companies 15
Sedation - Companies Involved in Therapeutics Development 16
Advicenne Pharma 16
AstraZeneca Plc 17
Concert Pharmaceuticals, Inc. 18
Drawbridge Pharmaceuticals Pty Ltd 19
Jiangsu Nhwa Pharma Corporation 20
NanoMedex Pharmaceuticals, Inc. 21
Paion AG 22
The Medicines Company 23
Sedation - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
ABP-700 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ADV-6209 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
alphaxalone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
clonidine hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CTP-354 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
propofol - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
propofol microemulsion - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
remimazolam - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Agonize GABA-A for Sedation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Sedation - Recent Pipeline Updates 44
Sedation - Dormant Projects 49
Sedation - Discontinued Products 50
Sedation - Product Development Milestones 51
Featured News & Press Releases 51
May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward 51
Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 52
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 53
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 53
Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 54
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 54
Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials 56
Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids 56
Jun 18, 2014: Drawbridge Pharmaceuticals granted new anaesthesia patent for Phaxan in China 57
Apr 16, 2014: Drawbridge Pharmaceuticals announces successful clinical trial results for Phaxan and grant of US patent 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for Sedation, H2 2015 8
Number of Products under Development for Sedation - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Sedation - Pipeline by Advicenne Pharma, H2 2015 16
Sedation - Pipeline by AstraZeneca Plc, H2 2015 17
Sedation - Pipeline by Concert Pharmaceuticals, Inc., H2 2015 18
Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2015 19
Sedation - Pipeline by Jiangsu Nhwa Pharma Corporation, H2 2015 20
Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2015 21
Sedation - Pipeline by Paion AG, H2 2015 22
Sedation - Pipeline by The Medicines Company, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 31
Sedation Therapeutics - Recent Pipeline Updates, H2 2015 44
Sedation - Dormant Projects, H2 2015 49
Sedation - Discontinued Products, H2 2015 50